36th week of 2022 patent applcation highlights part 23 |
Patent application number | Title | Published |
20220281898 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are compounds having Formula I: | 2022-09-08 |
20220281899 | COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME - Provided are the following compound and a fluorescently labeled biological substance having this fluorescent compound. | 2022-09-08 |
20220281900 | MODIFIED LECITHIN FOR ASPHALT APPLICATIONS - Embodiments of the present invention provide a method, comprising obtaining a lecithin-containing material, in some aspects derived from a crude refining stream, comprising 20-80 wt % acetone insoluble matter, 1-30 wt % free fatty acid, and less than 10 wt % water, adding a fatty acid or carboxylic source to the lecithin-containing material to obtain a lecithin fatty acid blend or lecithin carboxylic acid blend and incorporating the blend into asphalt or oil field applications. | 2022-09-08 |
20220281901 | TRIARYL PHOSPHINE LIGANDS, PREPARATION METHOD THEREFOR, AND USE IN CATALYSING COUPLING REACTIONSONS - Triaryl phosphine ligands, as shown in general formulae Ia and Ib, or a mixture thereof, and a preparation method therefor. The invention addresses the deficiencies of biaryl phosphine ligands invented by Buchwald et al. Also provided are a triaryl phosphine coordinated palladium complex, a system composed of triaryl phosphine ligand and a palladium salt or complex, and a use of the triaryl phosphine coordinated palladium complex in catalysing organic reactions, in particular a use in catalysis of coupling reactions involving (pseudo)halogenated aromatic hydrocarbon as substrate. | 2022-09-08 |
20220281902 | MITOCHONDRIAL MODULATION TO IMPROVE METABOLIC SYNDROME DURING AGING - Compounds, compositions and methods are provided for mitochondrial modulation. The subject mitochondrial modulator compounds generally include a head group linked to a charged moiety. In certain cases, the head group is a heterocyclic or a heteroaryl group. Aspects of the subject methods include a method of modulating mitochondria. Aspects of the subject methods include treating a subject having a metabolic syndrome-related disease or a symptom thereof by administering to the subject a therapeutically effective amount of a subject compound. In certain cases, the disease is selected from hyperlipidemia, type 2 diabetes, fatty liver disease, obesity, cardiovascular disease and stroke. In certain cases, the symptom is selected from abdominal obesity, insulin resistance, hyperinsulinemia, high levels of blood fats, increased blood pressure, and elevated serum lipids. | 2022-09-08 |
20220281903 | FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES - The invention relates to a flavonoid derivative containing a flavonoid that is coupled to an alkylene group via an ether bond, said alkylene group having an adhesion group for adhesion onto a dental surface. The flavonoid derivative has a long-term suppressing effect on the dental disease-causing formation of biofilm on the dental surfaces treated with the flavonoid derivative. The invention further relates to a kit for producing such a flavonoid derivative, and to the use of same. | 2022-09-08 |
20220281904 | A PRODRUG PLATFORM USEFUL TO DELIVER AMINES, AMIDES AND PHENOLS - A prodrug platform is useful to deliver pharmaceutically active amines, amides and phenols and their use in the diagnosis, prevention and/or treatment of various diseases. Compared with the parent drug (e.g., Gemcitabine), the prodrugs show a significant overall safety improvement (therapeutic index (TI) improvement), especially in liver. The prodrugs can treat several diseases, including, for example, cancer, metabolic disease, viral infection, immunological disease, neurologic disease, and blood disease. | 2022-09-08 |
20220281905 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound comprising a metal M and a ligand L | 2022-09-08 |
20220281906 | METHODS AND COMPOSITIONS FOR PREPARING NUCLEIC ACIDS THAT PRESERVE SPATIAL-PROXIMAL CONTIGUITY INFORMATION - Provided herein are methods and compositions for preparing nucleic acids in samples that preserve spatial-proximal contiguity information. Samples include, but are not limited to, formalin-fixed paraffin-embedded (FFPE) samples, deeply formalin-fixed samples and samples that comprise protein:cfDNA complexes. | 2022-09-08 |
20220281907 | Modified hexa-acylated neisserial LPS - The present invention relates to neisserial LPS having a hexa-acylated lipid A moiety, wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it comprises a palmitoleoyl instead of a lauroyl secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention further relates to mixtures of the hexa-acylated LPS with the corresponding penta-acylated LPS, lacking a secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention also relates to neisserial bacteria that have been genetically modified to reduce expression of the endogenous 1pxL1 gene and to introduce expression of a heterologous thermosensitive 1pxP gene for producing the hexa- and penta-acylated LPS. By selecting the time and/or temperature at which the bacterium is grown, it is feasible to increase or decrease the amount of hexa-acylated lipid A structure relative to the corresponding penta-acylated structure and thereby modulate the TLR4 agonist activity of the neisserial LPS of the invention, to the exact level of activity required for a particular immunotherapeutic approach. | 2022-09-08 |
20220281908 | 8-FLUORO-4-ALKYLUMBELLIFERYL ALPHA-D-GLUCOPYRANOSIDE, BIOLOGICAL STERILIZATION INDICATOR INCLUDING THE SAME AND ITS USE IN A METHOD OF DETERMINING EFFICACY OF A STERILIZATION PROCESS - A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a composition, wherein the composition comprises the enzyme substrate, wherein if the frangible container is broken the composition will contact the bacterial spores to form a mixture having an initial pH in the range from 6.0 to 9.0. The enzyme substrate comprises a fluorinated 4′-alkylumbelliferyl α-D-glucopyranoside represented by the structural formula (I), wherein R is an alkyl group having from 1 to 12 carbon atoms. A biological sterilization indicator comprising a kit containing isolated components comprising (i) bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of the enzyme substrate and a method of assessing efficacy of a sterilization process are also disclosed. | 2022-09-08 |
20220281909 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS - A D-galactopyranose compound of formula (1) | 2022-09-08 |
20220281910 | DINUCLEOTIDE COMPOUNDS FOR TREATING CANCERS AND MEDICAL USES THEREOF - The present disclosure provides the dinucleotide compounds which is useful for treating various cancers. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating cancer. The present disclosure also provides a method of treatment of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment. | 2022-09-08 |
20220281911 | OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE - The disclosure relates to GalNAc moieties comprising at least one GalNAc monomer. The disclosure also relates to GalNAc-oligonucleotide conjugates comprising GalNAc moieties and oligonucleotides, e.g., saRNAs or siRNAs useful in regulating the expression of a target gene. Methods of using the GalNAc-oligonucleotide conjugates are also provided. | 2022-09-08 |
20220281912 | COMPOUNDS FOR USE IN THE TREATMENT OF LIVER DISEASE - Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease. | 2022-09-08 |
20220281913 | INTRAGEL WELL SAMPLE LOADING SYSTEM - The present invention provides a protein separation micro el having a first plate having a first opening; a second plate; a gel substrate formed between the first plate and the second plate; and a plurality of wells positioned at a first non-zero distance from a first edge of the gel and at a second non-zero distance from a second edge of the gel; wherein the first and second edge of the gel are opposite edges of the gel. | 2022-09-08 |
20220281914 | PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME - The instant invention relates to compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, e.g., an anti-GM-CSFRα antibody or antigen binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such compositions. Methods for using such compositions to treat a disorder, e.g., a GM-CSFRα-associated disorder, are also provided. | 2022-09-08 |
20220281915 | COMPOSITIONS COMPRISING BOVINE ADRENAL MEDULLA 8-22 (BAM8-22) PEPTIDE ANALOGS AND METHODS OF USE - The present disclosure relates to, among other things, compositions and methods for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, and pain resulting from nerve injury or nerve degeneration. In some embodiments, the pain can be resulting from an inflammatory condition, dysesthesia, or allodynia. The present disclosure also relates to methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. | 2022-09-08 |
20220281916 | POLYPEPTIDE AND USE THEREOF - The present disclosure discloses use of a polypeptide, relating to the field of biopharmaceuticals. The polypeptide comprises the following domains: Pro-Arg-Cys-X-Y-Gly-Glu, where X is Trp or Tyr, and Y is Arg or Cys; and Arg-Gly-Ala-Asp-Arg-Ala; or a sequence of any amino acid mutated in the foregoing domains. The polypeptide can be used for treating various fibrosis diseases and symptoms, including pulmonary fibrosis, hepatic fibrosis, myelofibrosis, renal fibrosis, myocardial fibrosis, skin fibrosis, and lung tissue lesions. | 2022-09-08 |
20220281917 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER - A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer. | 2022-09-08 |
20220281918 | PBP BINDING BICYCLIC PEPTIDE LIGANDS - The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection. | 2022-09-08 |
20220281919 | pH-SENSITIVE CYCLIC PEPTIDES - The present subject matter provides pH triggered peptides, as well as compositions methods, devices, and systems comprising the same. The pH triggered peptides include cyclic and short linear peptides, and may have higher affinity to a membrane lipid bilayer at low pH than at neutral or high pH. | 2022-09-08 |
20220281920 | BICYCLIC PEPTIDYL INHIBITORS - The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the IκB kinase α/β (IKKα/β)-binding domain of NF-κB essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKKβ interaction, thereby selectively inhibiting canonical NF-κB signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells. | 2022-09-08 |
20220281921 | ONCOLYTIC NON-HUMAN ADENOVIRUSES AND USES THEREOF - Novel nucleic acid sequences, vectors and adenoviral genomes are provided herein. Corresponding novel adenoviruses and genotypes and compositions are also provided. The novel nucleic acid sequences, vectors, genomes, adenoviruses, genotypes and compositions are useful in therapy. The novel nucleic acid sequences, vectors, genomes, adenoviruses, genotypes and compositions are particularly useful in treating or preventing cancer. | 2022-09-08 |
20220281922 | AAV VARIANTS WITH ENHANCED TROPISM - The disclosure relates to compositions, methods, and processes for the preparation, use, and/or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue. | 2022-09-08 |
20220281923 | AAV CAPSID VARIANTS FOR GENE THERAPY - Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues. Provided here are variant AAV capsid proteins and variant capsid protein containing particles. Compositions of these variant AAV particles can be used to alter tissue tropism and transduction efficiency. In some embodiments, compositions described in this application are useful to produce rAAV particles, and/or to deliver one or more genes of interest to a target tissue. | 2022-09-08 |
20220281924 | ENGINEERED HEPATITIS B CORE POLYPEPTIDE - Genetically modified HBc polypeptides are provided. | 2022-09-08 |
20220281925 | Chimeric Papilloma Virus L1 Protein - The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines. | 2022-09-08 |
20220281926 | DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME - The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections. | 2022-09-08 |
20220281927 | NOVEL CHIMERIC INSECTICIDAL PROTEINS TOXIC OR INHIBITORY TO LEPIDOPTERAN PESTS - Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins. | 2022-09-08 |
20220281928 | CRM197 PROTEIN EXPRESSION METHOD - The present invention relates to a signal sequence for expressing a CRM197 protein in Escherichia coli and secreting same into the periplasm, and a use thereof, and more specifically, to: a signal sequence for expressing a CRM197 protein; a nucleic acid for coding the signal sequence; a nucleic acid construct or expression vector comprising the nucleic acid and a CRM197 protein gene; a recombinant microorganism having the nucleic acid construct or expression vector introduced therein; and a CRM197 protein production method comprising a step for culturing the recombinant microorganism. According to the present invention, a CRM197 protein having the same physicochemical/immunologic properties as the protein isolated from the parent bacteria may be expressed even in regular Escherichia coli of which a redox potential is not adjusted, and a CRM197 protein having high periplasmic secretion efficiency may be produced even without shifting the pH of a culture medium in order to increase secretion into the periplasm, and thus the present invention is very useful in CRM197 protein production. | 2022-09-08 |
20220281929 | METHOD FOR THE TREATMENT OF A RELAPSING-REMITTING CONDITION - The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim | 2022-09-08 |
20220281930 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH - The present disclosure provides, in part, composition and methods for the treatment of pathological pain and itch. | 2022-09-08 |
20220281931 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION - The invention features methods for characterizing a cancer as sensitive or resistant to Bcl6 therapies, as well as compositions and methods for inducing the degradation or polymerization of a polypeptide of interest. | 2022-09-08 |
20220281932 | METHODS AND COMPOSITIONS FOR REGENERATING TISSUES - Provided are methods for promoting the healing of injuries to tendons and ligaments by administering a NELL1 protein or a nucleic acid encoding a NELL1 protein to a subject in need thereof. Also provided are NELL1 compositions and methods for promoting tissue regeneration, promoting the healing of wounds, and enhancing fibroblast migration, proliferation, or both migration and proliferation. | 2022-09-08 |
20220281933 | FUSION TOXIN PROTEINS FOR TREATMENT OF DISEASES RELATED TO CMV INFECTIONS - The present invention relates to immunotoxins useful in treating diseases related to CMV infection. The invention also relates to use of the immunotoxin and pharmaceutical compositions comprising the immunotoxin as a medicament, and a kit for treatment or prevention of CMV infection comprising the immunotoxin. | 2022-09-08 |
20220281934 | T-CELL MOBILIZING CXCL10 MUTANT WITH INCREASED GLYCOSAMINOGLYCAN BINDING AFFINITY - Herein provided is a novel recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10 and increasing T-cell mobilization and its use for preventing or treating inflammatory and immuno-logical disorders and auto-immune diseases. | 2022-09-08 |
20220281935 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 - The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders. | 2022-09-08 |
20220281936 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS - he disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent. | 2022-09-08 |
20220281937 | FUSION MOLECULES AND IL-15 VARIANTS - The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention. | 2022-09-08 |
20220281938 | Biotechnology for curing hypothyroidism - A method and apparatus for thyroid hormone control using a synthetic module containing thyroid hormone and an intelligent valve control device. In embodiments, the invention consists of an iterative process with three steps. First, blood is measured to detect thyroid hormone concentration. Second, the measured concentration is compared to a target thyroid hormone concentration. Third, the intelligent valve control device optimizes thyroid hormone delivery, correcting for differences between the measured concentration and the target concentration. | 2022-09-08 |
20220281939 | MODIFIED TFF2 POLYPEPTIDES - Described herein are modified TFF2 polypeptides, compositions comprising these polypeptides and their use to treat cancer and inflammation. | 2022-09-08 |
20220281940 | MODIFIED FOLLICLE-STIMULATING HORMONE AND METHODS OF USING THE SAME - The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing, and methods of using the hypo-glycosylated FSH as disclosed herein. These methods of use include methods of treating infertility, methods of inducing follicle growth and/or maturation, methods of inducing oocyte/egg growth and/or maturation, methods of stimulating sex steroid secretion, methods of treating or preventing bone density loss, and methods of treating or preventing fatty tissue accumulation. | 2022-09-08 |
20220281941 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR - Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target. | 2022-09-08 |
20220281942 | T CELL RECEPTORS AND METHODS OF USE THEREOF - The present disclosure is directed recombinant T cell receptors capable of binding a CCND1 epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof. | 2022-09-08 |
20220281943 | CAR-T CELLS SPECIFIC FOR MODIFIED PROTEINS IN EXTRACELLULAR SPACES - Chimeric antigen receptor (CAR)-expressing Tregs specifically target modified protein or proteins present in the extra cellular matrix of an inflammatory lesion of patients to induce a localized and effective immunosuppressive response. | 2022-09-08 |
20220281944 | SPYCATCHER AND SPYTAG: UNIVERSAL IMMUNE RECEPTORS FOR T CELLS - The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor that comprises a protein or peptide tag, such as a SpyCatcher or a SpyTag moiety, bound to an extracellular hinge region, a transmembrane domain, and an intracellular domain for T cell activation. | 2022-09-08 |
20220281945 | CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF - Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells. | 2022-09-08 |
20220281946 | Compositions and Methods for Treating Cancer with DuoCARs - Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions. | 2022-09-08 |
20220281947 | Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof - The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression. | 2022-09-08 |
20220281948 | MHC CLASS II MOLECULES AND METHODS OF USE THEREOF - The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DP beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof. | 2022-09-08 |
20220281949 | MHC CLASS II MOLECULES AND METHODS OF USE THEREOF - The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DR beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof. | 2022-09-08 |
20220281950 | FASL EXPRESSION AND FASR GENE KNOCKOUT TO PROTECT THERAPEUTIC CELLS FROM ALLOGENEIC REJECTION AND ACTIVATION-INDUCED CELL DEATH - Compositions, methods, expression vectors and engineered immune cells for improving therapies that entail the administration of allogeneic cells to a patient. An immune cell, e.g., a T cell, modified to comprise and/or express FasL protein or a FasL protein derivative from, for example, an expression vector comprising a polynucleotide that encodes FasL protein or a FasL protein derivative, and to express FasR at a reduced level, and further modified to comprise and/or express an antigen binding protein e.g., a chimeric antigen receptor (CAR). An improved method of CAR T-cell therapy that comprises administering the improved immune cells, and compositions that comprise the improved immune cells. Methods of improving persistence of administered cells and reducing activation-induced cell death comprising administering the improved cells. | 2022-09-08 |
20220281951 | VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand. | 2022-09-08 |
20220281952 | NEURORECEPTOR COMPOSITIONS AND METHODS OF USE - The present disclosure provides compositions and methods for the treatment of neurological disorders. | 2022-09-08 |
20220281953 | COLLAGEN POWDER - There is a need to provide a collagen powder having desirable product characteristics, such as high fluid absorption capacity, while also having processing characteristics that allow commercial manufacturing and handling of the collagen powder. The present invention relates to a collagen powder, a method of manufacture thereof, and uses thereof. In particular, the present invention relates to a process for preparing a collagen powder, the process comprising the steps of providing a collagen source; adjusting the concentration of the collagen source; adjusting the pH of the collagen source; freezing the collagen source; dehydrating the frozen collagen; and degrading the dehydrated collagen to a powder. | 2022-09-08 |
20220281954 | RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF - This disclosure provides non-naturally occurring collagen and elastin molecules. The non-naturally occurring collagens and elastins include truncated collagens, truncated elastins, as well as fusion proteins thereof. The non-naturally occurring collagen and elastin are useful in foods, cosmetics and many other products and uses. | 2022-09-08 |
20220281955 | MICROBE-BINDING MOLECULES AND USES THEREOF - Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can not only bind or capture of a microbe or microbial matter thereof, but they also have improved capability (e g, enhanced sensitivity or signal intensity) of detecting a microbe or microbial matter. Thus, the microbe-targeting molecules, microbe-targeting articles, and/or the kit described herein can be used in various applications, e.g., but not limited to assays for detection of a microbe or microbial matter, diagnostic and/or therapeutic agents for diagnosis and/or treatment of an infection caused by microbes in a subject or any environmental surface, and/or devices for removal of a microbe or microbial matter from a fluid. | 2022-09-08 |
20220281956 | METHOD FOR PRODUCING A MATERIAL USING COLLAGEN FROM CULTURED ANIMAL CELLS - Methods to produce a material or a woven or non-woven fabric using collagen isolated from cultured animal cells and/or tissue cultures are described herein. The methods include molding the isolated collagen, treating native collagen and/or an extracellular matrix, and/or combining isolated layered collagen, an extracellular matrix, and/or a connective tissue with other organic and/or non-organic components. | 2022-09-08 |
20220281957 | MODIFIED HUMAN VARIABLE DOMAINS - The present invention provides polypeptides comprising modified human, humanized, or chimeric immunoglobulin heavy chain variable domains. Corresponding antibodies, variants, fragments, nucleic acids, vectors, phages, libraries, methods and kits are also provided. | 2022-09-08 |
20220281958 | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) - The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof. | 2022-09-08 |
20220281959 | ANTIBODIES AND THE USES THEREOF - The present invention relates to antibodies and their use. The invention particularly relates to antibodies against a particular domain of gp41, pharmaceutical compositions or kits or any device comprising the same, as well as the uses thereof. The invention is particularly useful for treating (e.g., curing or preventing), detecting or monitoring AIDS in a subject, either, alone or in combination with other treatments/agents. | 2022-09-08 |
20220281960 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUBERCULOSIS - A human antibody comprising an antigen binding domain which binds PstS1 of | 2022-09-08 |
20220281961 | PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASE - The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes. | 2022-09-08 |
20220281962 | TETRANECTIN-TARGETING MONOCLONAL ANTIBODIES TO FIGHT AGAINST LETHAL SEPSIS AND OTHER PATHOLOGIES - Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments. | 2022-09-08 |
20220281963 | METHODS FOR TREATING ALZHEIMER'S DISEASE - Provided are methods for treating Alzheimer's disease in a human subject in need thereof when the subject develops an Amyloid Related Imaging Abnormality (ARIA) during a treatment regimen comprising administration of multiple doses of an anti-beta-amyloid antibody (e.g., BIIB037) to the subject. | 2022-09-08 |
20220281964 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 2022-09-08 |
20220281965 | ANTIBODIES DIRECTED AGAINST GDF-15 - The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15. | 2022-09-08 |
20220281966 | ANTI-IL13 ANTIGEN BINDING PROTEINS - The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. | 2022-09-08 |
20220281967 | NOVEL IL-17B ANTIBODIES - The invention relates to novel IL-17B antagonist antibodies and their use in the diagnosis or treatment of IL-17B mediated diseases. | 2022-09-08 |
20220281968 | METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES - The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof. | 2022-09-08 |
20220281969 | ANTIBODIES THAT BIND TO LRP6 PROTEINS AND METHODS OF USE - Provided herein are antibodies that specifically bind LRP6 and method of use thereof. | 2022-09-08 |
20220281970 | Pharmaceutical Combinations - The present invention relates to the combination of the HDM2-p53 interaction inhibitor drug (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and an anti-TIM-3 antibody molecule as TIM-3 inhibitor. The present invention further relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention further relates to dose and dosing regimen related to this combination cancer treatment. | 2022-09-08 |
20220281971 | Functional Binders Synthesized and Secreted by Immune Cells - The invention relates to an in vivo functional ligands (IFLs) including a single-chain variable fragment (scFv) domain, a fragment crystallizable (Fc) domain, and a hinge domain joining the scFv and Fc domains The IFLs specifically bind target receptors and are capable of triggering antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), as well as cytokine stimulation. The IFLs may be joined to a chimeric antigen receptor via a self-cleaving peptide. The IFLs may be expressed in immune cells, such as a natural killer cell or a T lymphocyte. Vectors, host cells, and methods of making IFLs are also described. | 2022-09-08 |
20220281972 | FORMULATION COMPRISING ANTI-PD-1/HER2 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME AND USE THEREOF - The present invention relates to formulations comprising an anti-PD-1/HER2 bispecific antibody, and in particular to a pharmaceutical formulation comprising the anti-PD-1/HER2 bispecific antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations. | 2022-09-08 |
20220281973 | ANTIBODIES AND BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER - Disclosed herein are antibodies that specifically bind to LRIG1 and methods of use thereof. In some embodiments, also described herein are methods of modulating immune system activity or promoting immune cell proliferation with an antibody that specifically binds to LRIG1. | 2022-09-08 |
20220281974 | TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY - The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration. | 2022-09-08 |
20220281975 | TREM2 ANTIBODIES AND USES THEREOF - The present invention relates to TREM2 antibodies, and uses thereof, for treating diseases such as neurodegenerative diseases. | 2022-09-08 |
20220281976 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2022-09-08 |
20220281977 | BISPECIFIC ANTIBODY - A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases. | 2022-09-08 |
20220281978 | Compositions and Methods for the Treatment of Cancer (Anti-ICOS Antibody Dosing) - Methods of treating cancer with particular doses of anti-ICOS antibodies are provided. | 2022-09-08 |
20220281979 | ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER - The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1. | 2022-09-08 |
20220281980 | ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF - The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody. | 2022-09-08 |
20220281981 | CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS - The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G β2M-free or β2M-associated immunosuppressive isoforms respectively. | 2022-09-08 |
20220281982 | BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY - Described herein are single vectors that, when expressed in cytolytic immune cells, results in both the expression of (1) a CAR targeting tumor-associated antigens and (2) secretion of a bispecific antibody that on one end recognizes NKG2D expressed on both innate and antigen specific cytolytic immune cells and on the other end targets tumor associated antigens. Unexpectedly, these modifications to the T cells result in enhanced survival and proliferation in vivo. Thus, therapeutic and diagnostic uses are disclosed. | 2022-09-08 |
20220281983 | METHODS FOR PROMOTING T CELLS RESPONSE - The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof. | 2022-09-08 |
20220281984 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF - Provided herein are antigen-binding protein constructs capable of specifically binding MET or an epitope of MET presented on surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs. | 2022-09-08 |
20220281985 | SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS - The present invention relates to the field of biomedicine and antibody engineering. Specifically, it relates to mono and multispecific multivalent single chain polypeptide molecules and derivatives thereof, preferably to multispecific single chain (tandem) trimerbodies with defined stoichiometry, to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, use as diagnostics or imaging reagents and combination therapies using thereof. | 2022-09-08 |
20220281986 | COMPOSITIONS AND METHODS TO BLOCK AND BIND CXCR4 TO MODULATE CELLULAR FUNCTION - Provided are composition comprising antibodies directed to the N-terminal domain of CXCR4. The antibody may be a scFv and can be fused to a RNA binding peptide. The fusion protein can be complexed to RNAi, such as micro RNA. The complexes can be used for targeting delivery of RNAi molecules to CXCR4 expressing cancer cells, as well as inhibiting the binding of CXCR4 to CXCL12. | 2022-09-08 |
20220281987 | METHODS FOR THE TREATMENT OF GPP - The present invention relates to the treatment of or alleviation of signs and symptoms of GPP or an acute phase flare-up of generalized pustular psoriasis (GPP) with anti-IL36R antibodies. | 2022-09-08 |
20220281988 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION - The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation. | 2022-09-08 |
20220281989 | GPCR BINDING PROTEINS AND SYNTHESIS THEREOF - Provided herein are methods and compositions relating to G protein-coupled receptor (GPCR) libraries having nucleic acids encoding for a scaffold comprising a GPCR binding domain. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein. | 2022-09-08 |
20220281990 | ANTI-TNFR2 ANTIBODIES AND USES THEREOF - Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases. | 2022-09-08 |
20220281991 | ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS - The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses. | 2022-09-08 |
20220281992 | TARGETED CHIMERIC PROTEINS AND USES THEREOF - The present invention relates, in part, to chimeric proteins comprising at least one targeting moiety that recognizes and binds SIRP1α and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases. | 2022-09-08 |
20220281993 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases - The present invention pertains to the field of immunotherapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (MDSC) into non suppressive cells, by administering a compound blocking the interaction between SIRPa and CD47 to a patient in need thereof, in order to reduce MDSC-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation. | 2022-09-08 |
20220281994 | Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof - MAGE-A4, or Melanoma-Associated Antigen A4, is a cancer-testis antigen (CTA) on the X chromosome. The present disclosure provides MAGE-A4-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present disclosure are capable of inhibiting the growth of tumors expressing MAGE-A4. The engineered cells of the present disclosure are useful for the treatment of diseases and disorders in which an upregulated or induced MAGE-A4-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the MAGE-A4-specific chimeric antigen receptors of the present disclosure are useful for the treatment of various cancers. | 2022-09-08 |
20220281995 | ANTI-FAP ANTIBODIES AND METHODS OF USE - The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same. | 2022-09-08 |
20220281996 | Compositions and Methods to Regulate Renalase in the Treatment of Cancer - The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics. | 2022-09-08 |
20220281997 | Anti-VHH Domain Antibodies and Use Thereof - The invention provides a group of anti-VHH domain antibodies and use thereof. The present invention further provides use of the described antibodies in the development, screening and purification of nano-antibodies, and use of the described antibodies in the field of immunotherapy. | 2022-09-08 |